377
Participants
Start Date
January 31, 2013
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
Exenatide once weekly suspension
Exenatide suspension 2 mg weekly subcutaneous injection
Exenatide twice daily
5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
Research Site, New Windsor
Research Site, Endwell
Research Site, Harleysville
Research Site, Manassas
Research Site, Hyattsville
Research Site, Columbia
Research Site, Elkridge
Research Site, Richmond
Research Site, Norfolk
Research Site, Greensboro
Research Site, Charleston
Research Site, Mt. Pleasant
Research Site, Ponte Vedra
Research Site, DeLand
Research Site, Oviedo
Research Site, Orlando
Research Site, Coral Gables
Research Site, Miami
Research Site, Palm Harbor
Research Site, Kissimmee
Research Site, Muscle Shoals
Research Site, Port Gibson
Research Site, Lexington
Research Site, Paducah
Research Site, Columbus
Research Site, Cincinnati
Research Site, Cincinnati
Research Site, Troy
Research Site, Detroit
Research Site, Edina
Research Site, Butte
Research Site, Chicago
Research Site, Chicago
Research Site, St Louis
Research Site, Lake Charles
Research Site, Little Rock
Research Site, Oklahoma City
Research Site, Oklahoma City
Research Site, Dallas
Research Site, Houston
Research Site, San Antonio
Research Site, Denver
Research Site, Salt Lake City
Research Site, Murray
Research Site, Phoenix
Research Site, Mesa
Research Site, Henderson
Research Site, Los Angeles
Research Site, Lomita
Research Site, Spring Valley
Research Site, Escondido
Research Site, Santa Ana
Research Site, Garden Grove
Research Site, Walnut Creek
Research Site, Portland
Research Site, Olympia
Research Site, Spokane
Research Site, New Bedford
Lead Sponsor
AstraZeneca
INDUSTRY